Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma

Ning‐Fang Ma(Queen Mary Hospital), Liang Hu(Queen Mary Hospital), Jackie M-W. Fung(Queen Mary Hospital), Dan Xie(Sun Yat-sen University), Bo‐Jian Zheng(University of Hong Kong), Leilei Chen(Queen Mary Hospital), Dongjiang Tang(Queen Mary Hospital), Li Fu(Queen Mary Hospital), Zhenguo Wu(Hong Kong University of Science and Technology), Muhan Chen(Queen Mary Hospital), Yan Fang(Sun Yat-sen University), Xin‐Yuan Guan(Sun Yat-sen University)
Hepatology
November 19, 2007
Cited by 161Open Access
Full Text

Abstract

UNLABELLED: Amplification of 1q21 is the most frequent genetic alteration in human hepatocellular carcinoma (HCC), being detected in 58%-78% of primary HCC cases by comparative genomic hybridization. Recently, we isolated a candidate oncogene, Amplified in Liver Cancer 1 (ALC1), from 1q21 by hybrid selection. Here we demonstrate that ALC1 was frequently amplified and overexpressed in HCC. ALC1-transfected cells possessed a strong oncogenic ability, increasing the colony formation in soft agar and increasing the tumorigenicity in nude mice, which could be effectively suppressed by small interfering RNA against ALC1. Functional studies showed that overexpression of ALC1 could promote G1/S phase transition and inhibit apoptosis. Molecular studies revealed that the oncogenic function of ALC1 might be associated with its roles in promoting cell proliferation by down-regulating p53 expression. CONCLUSION: These results suggest that ALC1 is the target oncogene within the 1q21 amplicon and plays a pivotal role in HCC pathogenesis.


Related Papers